Drug intelligence / Profile preview

Juhuashuxin tablet

Development stage: Unknown
Lead developer: Xiyuan Hospital
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Juhuashuxin tablet is a botanical drug candidate developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences (CACMS) for the treatment of cardiovascular diseases, including angina pectoris and coronary heart disease. It is a Traditional Chinese Medicine (TCM) formulation, likely utilized as a hospital preparation, intended to improve coronary circulation and provide cardioprotective effects. Clinical evaluation has included Phase 1 studies to assess the pharmacokinetics and pharmacodynamics of the tablet in healthy volunteers.

Brand names: Chrysanthemum Shuxin Tablets
Other names: 菊花舒心片Juhua Shuxin Pian

Beyond the preview

Go deeper on Juhuashuxin tablet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juhuashuxin tablet.

Explore the full profile